Key regions: Australia, Japan, United States, Germany, Europe
Belarus, a landlocked country in Eastern Europe, has been experiencing a steady growth in the Anti-Coagulants market.
Customer preferences: The Belarusian population has been showing a growing concern towards cardiovascular diseases, which has been driving the demand for anti-coagulants. The rise in the aging population has also contributed to the growth of the market as the elderly are more prone to heart diseases and require long-term medication.
Trends in the market: The Anti-Coagulants market in Belarus is dominated by the oral anti-coagulants segment, which has been growing at a faster rate than the injectable anti-coagulants segment. This can be attributed to the convenience of oral medication and the ease of administration. Additionally, there has been a shift towards the use of novel oral anti-coagulants (NOACs) from traditional anti-coagulants such as warfarin due to their superior efficacy and safety profiles.
Local special circumstances: Belarus has a centralized healthcare system, which means that the government plays a significant role in the procurement and distribution of drugs. The government regulates the prices of drugs, which can affect the profitability of pharmaceutical companies operating in the country. Additionally, the country has a low GDP per capita, which means that the affordability of drugs is a significant concern for the population.
Underlying macroeconomic factors: The Belarusian economy has been growing at a slow pace, with a significant dependence on Russia for its energy needs. The country has been facing economic sanctions from the West, which has affected its trade and investment opportunities. The healthcare sector in Belarus is also underfunded, which has led to a shortage of medical personnel and a lack of modern medical equipment. These factors can affect the growth of the Anti-Coagulants market in the country. In conclusion, the Anti-Coagulants market in Belarus has been growing steadily due to the rising prevalence of cardiovascular diseases and the aging population. The market is dominated by the oral anti-coagulants segment, and there has been a shift towards the use of NOACs. The centralized healthcare system and low GDP per capita are significant concerns for the affordability and profitability of drugs in the country. The slow economic growth and underfunded healthcare sector can also affect the growth of the market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
